PT  - JOURNAL ARTICLE
AU  - Bamba, Gaye
AU  - abboud, Joelle Abi
AU  - Olal, Emmanuel
AU  - Kitara, David Lagoro
TI  - Comparative analysis of the evolution of Life Expectancy in the United Republic of Tanzania, Uganda, and Kenya in 61 years (1960-2021): A secondary data analysis of the World Population Prospects (WPPs) on the three East African countries
AID  - 10.1101/2024.04.12.24305722
DP  - 2024 Jan 01
TA  - medRxiv
PG  - 2024.04.12.24305722
4099  - http://medrxiv.org/content/early/2024/04/13/2024.04.12.24305722.short
4100  - http://medrxiv.org/content/early/2024/04/13/2024.04.12.24305722.full
AB  - Background Life expectancy at birth (LE0) in Kenya, Uganda, and the United Republic of Tanzania in 1960 was 57, 54, and 42 years, respectively. However, in 2019, LE0 had gained in Kenya, Uganda, and Tanzania to 62.94, 62.99, and 66.99 years, respectively. This study aimed to evaluate and compare the progression of LE0 in Kenya, Uganda, and Tanzania over 61 years (1960-2021).Methods Life tables from World Population Prospects (WPPs) were used to calculate LE0 for Kenya, Uganda, and Tanzania by sex from 1960 to 2021. LE0 was contextualized alongside trends in 1960 and 2019. Using decomposition techniques, we examined how each sex contributed to losses or gains in LE0 between 1960 and 2021 and the likely contributory factors to LE0 losses. RStudio software was used to calculate differences in LE0 from one year to another. Linear regression analyses were used to trace the progression of LE0 in Kenya, Uganda, and Tanzania in six decades.Results LE0 improved from 1960 to 2021 in males and females in Kenya, Uganda, and Tanzania. The most substantial improvement occurred between 1960-1980 in Kenya and Tanzania while in Uganda between 1960-1970. LE0 losses were observed between 1980-2000, and 2020-2021 in Kenya and Tanzania while Uganda experienced losses between 1970-1981; 1989-1993, and 2020-2021. LE0 losses in Kenya, Uganda, and Tanzania were likely a result of deaths related to high infant, maternal, and child mortality rates due to infectious and non-communicable diseases (1990-2021). In Uganda, the political and economic turmoil during Amin’s regime (1971-1979) registered the most substantial LE0 losses over the period. In addition, LE0 gaps between males and females fluctuated over the years with the highest at 9.5 years in Uganda in 1982 and the lowest at 2.25 years in Kenya in 2001. The fluctuating LE0 gaps between males and females has been observed in the three East African countries.Conclusion LE0 in Kenya, Uganda, and Tanzania progressively increased from 1960-2021. Males and females showed fluctuating LE0 gaps in the last 61 years but females lived longer than males. There were LE0 losses between 1970-2000 and between 2020-2021. High infant, maternal, and child mortality rates, and later, the high prevalence of HIV and AIDS, immunizable diseases, and the COVID-19 pandemic were the likely reasons for LE0 losses. The COVID-19 pandemic contributed to LE0 losses more in Kenya than Tanzania and Uganda likely due to deaths related to the virus itself or the control measures.LE0 losses in Uganda in the 70s were likely due to political and economic turmoil during the brutal Amin’s regime. Even though many studies show LE0 gains in Kenya, Uganda, and Tanzania over the 61 years, political and economic stability, economic growth, health systems strengthening, control of infectious diseases, and epidemics were critical in the LE0 gains. Thus, a more comprehensive study is warranted to assess the actual impact of public health interventions in LE0 gains in the three East African countries.Competing Interest StatementThe authors have declared no competing interest.Funding StatementThis study did not receive any funding.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:This study on life expectancy on the population of Kenya, Uganda, and the United Republic of Tanzania was obtained from a public repository, the United Nations World Population Prospects (WPPs) and we conducted secondary data analysis. In addition, the study followed all relevant institutional guidelines and regulations on managing open data sources. https://www.google.com/search?q=united+nations+world+population+prospects+(wpps)&oq=United+Nations+World+Population+Prospects+WPPs&gs_lcrp=EgZjaHJvbWUqBwgBECEYoAEyBggAEEUYOTIHCAEQIRigATIHCAIQIRigAdIBCjM4MzA1ajBqMTWoAgiwAgE&sourceid=chrome&ie=UTF-8I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.YesAll datasets supporting this article's conclusion are within this paper and are accessible by a reasonable request to the corresponding author. https://www.google.com/search?q=united+nations+world+population+prospects+(wpps)&oq=United+Nations+World+Population+Prospects+(WPPs&gs_lcrp=EgZjaHJvbWUqBwgBECEYoAEyBggAEEUYOTIHCAEQIRigATIHCAIQIRigAdIBCjM4MzA1ajBqMTWoAgiwAgE&sourceid=chrome&ie=UTF-8 AIDSAcquired Immune deficiency syndromeARTAntiretroviral therapyCDCUnited States Centres for Disease control and PreventionCOVID-19Coronavirus disease-19HIVHuman Immune VirusLE0Life expectancy at birthMDGsMillenium Development GoalsSARS-CoV-2Severe acute respiratory coronavirus-2SDGsSustainable Development GoalsWHOWorld Health OrganizationWPPsWorld Population Prospects